-
Product Insights
New![]()
Interporto Campano and CIS – Solar Plant
Interporto Campano and CIS - Solar Plant is a solar PV project located in Campania, Italy. The project is owned and developed by Enel SpA. The project is currently active. Empower your strategies with our Interporto Campano and CIS - Solar Plant report and make more profitable business decisions. Note: This is an on-demand report that will be delivered upon request. The report will be delivered within 2 to 3 business day of the purchase, excluding weekends and holidays. Certain...
-
Track & Monitor
New![]()
Innovation in automotive: CI engine controls
Why settle for outdated information when you can stay ahead of the curve with our comprehensive report? Our team of industry experts has meticulously researched and analyzed the latest trends, innovations, and emerging technologies in the automotive industry’s CI engine controls innovations. By leveraging our report, you'll gain invaluable insights that can revolutionize your business strategies and give you a competitive edge. Why Choose Our Report? Unparalleled Expertise: Our research team consists of seasoned analysts with deep knowledge and experience...
-
Product Insights
![]()
Block CI-27 Complex Field, Cote d’Ivoire
Block CI-27 Complex upstream field is located in Gulf of Guinea, Cote d'Ivoire. The upstream field is owned by Energie De Cote D’Ivoire SA (12%); Foxtrot International LDC (24%); Petroci Gaz (40%); Saur Energie Cote D'Ivoire (24%). It is operated by Foxtrot International LDC. The project started its operations in 1999. Block CI-27 Complex Upstream Field profile includes core details such as name, resource type, asset status, stage, owner and equity stakes, operator, product specs (gravity, CO2, sulphur), location, as...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – AB-248 in Head And Neck Squamous Cell Carcinoma (HNSC)
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. AB-248 in Head And Neck Squamous Cell Carcinoma (HNSC) Drug Details: AB-248 is under development...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – EG-501 in Cognitive Impairment
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.EG-501 in Cognitive ImpairmentDrug Details:EG-501 is under development for the treatment of cognitive impairment (CI) in...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – AB-248 in Metastatic Melanoma
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. AB-248 in Metastatic Melanoma Drug Details: AB-248 is under development for the treatment of locally...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – AB-248 in Non-Small Cell Lung Carcinoma
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. AB-248 in Non-Small Cell Lung Carcinoma Drug Details: AB-248 is under development for the treatment...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – AB-248 in Metastatic Renal Cell Carcinoma
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. AB-248 in Metastatic Renal Cell Carcinoma Drug Details: AB-248 is under development for the treatment...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – AB-248 in Solid Tumor
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. AB-248 in Solid Tumor Drug Details: AB-248 is under development for the treatment of locally...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – EG-501 in Systemic Lupus Erythematosus
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.EG-501 in Systemic Lupus Erythematosus Drug Details:EG-501 is under development for the treatment of cognitive impairment...
Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.